Project Grant 2449073
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Awardee
Plexymer, Inc. (U8KMX9MT1EP3)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
North Plainfield, NJ 07060, USA
Similar Awards
This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,864 to Core Biotherapeutics Inc. aims to develop a platform for disruptive drug candidates that can reprogram molecular networks to produce therapeutic effects beyond single-target approaches. The key objectives are to: 1) demonstrate that oligonucleotide drug efficacy is a function of transcription factor (TF) network reprogramming using a breast cancer cell line, 2) build a...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,932 to Femtofluidics Incorporated aims to develop hardware that will enable the rapid and inexpensive synthesis of DNA-encoded libraries (DELs). The goal is to expedite drug discovery and generate data to train artificial intelligence (AI) models, strengthening U.S. competitiveness in drug discovery and reinforcing leadership in automation and AI research. The technology will...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Delaqua Pharmaceuticals, Inc. aims to enhance the therapeutic use of hydrophobic drugs through a polymeric micelle approach to drug solubilization. The key objectives are to 1) improve the formulation of spherical micelles for enhanced stability and drug solubilization, 2) perform initial toxicity studies to establish the safety of the platform, and 3) demonstrate...
The National Science Foundation (NSF) awarded a $273,706 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Matmerize, Inc., a for-profit organization, to develop a physics-informed/encoded polymer informatics platform to accelerate the development of advanced polymers and formulations. The project aims to transform the way polymeric materials are developed by adopting advanced artificial intelligence techniques to dramatically expedite the...
The National Science Foundation (NSF) awarded a $365,887 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to The Research Foundation For The State University Of New York (RF SUNY) for the project "PFI-RP: PRECISION DIAGNOSTICS FOR PERSONALIZED CANCER CARE: DEVELOPMENT OF NEW DRUGS AND SELECTION OF TREATMENT". This project aims to develop an innovative artificial intelligence (AI) technology to select optimal treatment options tailored to...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...
This Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) provides $100,000 to the Georgia Tech Research Corporation to advance protein engineering through a novel interdisciplinary approach combining artificial intelligence (AI) methods and automated laboratory experimentation. The research aims to greatly accelerate the discovery of new proteins with enhanced properties, offering significant potential impact across scientific domains...
The National Science Foundation (NSF) awarded Pearl Bio, Inc., a biotechnology company, a $274,462 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funded the development of a next-generation biomanufacturing platform to engineer new microbial organisms and cellular machinery. This platform enables the incorporation of diverse, non-native components into proteins, creating a new class of biological materials for therapeutic development,...